Currently, cancer therapy remains limited by a “one-size-fits-all” approach, whereby treatment decisions are based mainly on the clinical stage of disease, yet fail to reference the individual's underlying biology and its role driving malignancy. Identifying better personalized therapies for cancer treatment is hindered by the lack of high-quality “omics” data of sufficient size to produce meaningful results and the ability to integrate biomedical data from disparate technologies. Resolving these issues will help translation of therapies from research to clinic by helping clinicians develop patient-specific treatments based on the unique signatures of patient's tumor. Here we describe the Georgetown Database of Cancer (G-DOC), a Web platfor...
Cancer therapy has historically been determined by a tumor’s tissue of origin. Now, thanks to advanc...
5Several major screenings of genetic profiling and drug testing in cancer cell lines proved that the...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
AbstractCurrently, cancer therapy remains limited by a “one-size-fits-all” approach, whereby treatme...
Cancer is one of the four major non-communicable diseases (NCD), responsible for similar to 14.6% of...
Notwithstanding decades of scientific and clinical investigation, cancer remains a disease that enda...
Notwithstanding decades of scientific and clinical investigation, cancer remains a disease that enda...
Cancer; of genomics and big data has brought the need for collaboration and data sharing in order to...
International audienceMotivation: Large pharmacogenomic screenings integrate heterogeneous cancer ge...
The Cancer Genomics Hub (CGHub) is the online repository of the sequencing programs of the National ...
The massive decrease in cost due to technological advances has made large-scale high-throughput data...
The Cancer Genomics Hub (CGHub) is the online repository of the sequencing programs of the National ...
The Cancer Genomics Hub (CGHub) is the online repository of the sequencing programs of the National ...
Precision medicine is at the forefront of innovation in cancer care. With the development of technol...
The complexity of human cancer underlies its devastating clinical consequences. Drugs designed to ta...
Cancer therapy has historically been determined by a tumor’s tissue of origin. Now, thanks to advanc...
5Several major screenings of genetic profiling and drug testing in cancer cell lines proved that the...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
AbstractCurrently, cancer therapy remains limited by a “one-size-fits-all” approach, whereby treatme...
Cancer is one of the four major non-communicable diseases (NCD), responsible for similar to 14.6% of...
Notwithstanding decades of scientific and clinical investigation, cancer remains a disease that enda...
Notwithstanding decades of scientific and clinical investigation, cancer remains a disease that enda...
Cancer; of genomics and big data has brought the need for collaboration and data sharing in order to...
International audienceMotivation: Large pharmacogenomic screenings integrate heterogeneous cancer ge...
The Cancer Genomics Hub (CGHub) is the online repository of the sequencing programs of the National ...
The massive decrease in cost due to technological advances has made large-scale high-throughput data...
The Cancer Genomics Hub (CGHub) is the online repository of the sequencing programs of the National ...
The Cancer Genomics Hub (CGHub) is the online repository of the sequencing programs of the National ...
Precision medicine is at the forefront of innovation in cancer care. With the development of technol...
The complexity of human cancer underlies its devastating clinical consequences. Drugs designed to ta...
Cancer therapy has historically been determined by a tumor’s tissue of origin. Now, thanks to advanc...
5Several major screenings of genetic profiling and drug testing in cancer cell lines proved that the...
The identification of novel candidate markers is a key challenge in the development of cancer therap...